Human Parvovirus B19 is a small, non‑enveloped DNA virus in the genus Erythrovirus of the family Parvoviridae. It has a linear, single‑stranded DNA genome and a pronounced tropism for human erythroid progenitor cells, which it infects via the P antigen on their surface.
Pathogenesis and Clinical Features
B19 was first recognized in 1974 and is the only parvovirus known to cause disease in humans. The virus replicates mainly in erythroid precursor cells in the bone marrow, leading to cessation of red‑cell production and transient anemia. In healthy children it typically causes erythema infectiosum (fifth disease), an illness characterized by mild fever, malaise and a “slapped cheek” facial rash. Adults may develop acute symmetric polyarthropathy involving the hands, wrists, knees or ankles. Infection in individuals with chronic hemolytic disorders such as sickle cell disease can precipitate a severe transient aplastic crisis, and persistent infection in immunocompromised hosts results in pure red‑cell aplasia with chronic anemia. Maternal infection during early pregnancy may lead to fetal infection, hydrops fetalis or miscarriage.
Examples and Notable Aspects
• In children, B19 infection manifests as fifth disease, where a bright erythematous facial rash is followed by a lacy rash on the trunk and limbs. • In patients with sickle cell disease or other hemoglobinopathies, the virus can cause a sudden drop in hemoglobin due to suppression of erythropoiesis. • Adults, particularly women, may experience arthralgia or arthritis without rash. • Persistent infection has been reported in people with HIV infection or those receiving immunosuppressive therapy. • The virus is resistant to lipid solvents and heat and can survive in the environment, making transmission via respiratory droplets and blood products possible. After infection the host immune response eventually clears the virus and confers long‑lasting immunity. Diagnosis is based on detection of specific IgM antibodies or viral DNA. There is currently no specific antiviral therapy; management focuses on supportive care. B19 remains an important consideration in patients presenting with rash, anemia or arthropathy, particularly in high‑risk groups. Related Terms: Erythrovirus, Fifth Disease, Aplastic Crisis, Hydrops Fetalis, Polyarthropathy